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Abstract
Rationale and purpose: Preliminary reports have suggested a possible ‘aetiology-specific’ efficacy of tiagabine (TGB)
in patients with drug-resistant partial epilepsy (DRPE) related to cerebral glial tumors (GTs). This efficacy should be
related to selective blocking of GAT-1 transporter by TGB. We presented our open-label, add-on TGB experience in
a group of patients with GTs, compared with other symptomatic DRPEs of different aetiology. Material and methods:
eleven patients with DRPE related to oligodendroglioma (six cases), astrocytoma (4) or multiform gliobastoma (1);
12 patients with DRPE related to a miscellanea of CNS lesions. TGB was added to previous AEDs, at dosage of
20–60 mg per die. Responders are defined by seizure frequency reduction 50% compared with baseline. Results:
Seven patients are responders with three seizure-free (SF) in GTs group, a rate of efficacy much higher than in
matching group (63.6 vs. 16.6%). Adverse events have been observed only rarely, not leading to discontinuation, in
GTs group. Conclusion: This preliminary observation seems to confirm the high efficacy and tolerability of TGB in
DRPE related to GTs. © 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Tiagabine (TGB) is a new antiepileptic drug
(AED), acting through the enhancement of
GABA-mediated inhibition. In detail, it selectively
blocks GAT-1 type of GABA transporter (Borden
et al., 1994) thus inhibiting the reuptake of GABA
and increasing its cerebral concentration in rodent
(Fink-Jensen et al., 1992) and in human (During
et al., 1992) synapses. Recent clinical studies
showed a long-term efficacy of TGB in about 30%
of patients with partial seizures (Loiseau, 1999;
Crawford et al., 2001).
One preliminary report has suggested TGB
could have a particular efficacy in epilepsy sec-
ondary to glial tumors (GTs) of the central ner-
vous system (CNS), likely related to its specific
mechanism of action (Dean et al., 1998).
In this paper, we report about the effect of TGB
add-on therapy in a group of patients with drug-
resistant partial epilepsy (DRPE) related to GTs.
In the attempt to demonstrate a possible ‘aetiol-
ogy-specific’ efficacy, the data are matched with a
group of symptomatic DRPEs related to a miscel-
lanea of CNS lesions.
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2. Methods
2.1. Population
Eleven patients (6 M, 5 F; age: 10–52 years,
mean: 32.5) with DRPE secondary to GTs. Clini-
cal data of this group are summarized in Table 1.
Ten patients had been submitted to surgical resec-
tion, and seven also to radiation therapy; the
specific aetiology, according to WHO criteria
(Kleihues et al., 1993), was: oligodendroglioma in
six cases, astrocytoma in three, and multiform
glioblastoma in one. Another patient, with a MRI
diagnosed astrocytoma, was inoperable, because
of his tumor location. Among the ten operated
patients, resection had been only partial in eight
of them. Epilepsy was characterized by simple
(SPS) or complex partial (CPS) seizures, with
secondary generalization in one case. All patients
were resistant to previous therapy, with at least
two seizures per month, and more than one
seizure per day in five patients, during the 2-
month baseline period. Epilepsy duration ranged
between 1 and 20 years (mean: 7.36). TGB was
added with a slow increasing schedule (5 mg every
week) to previous AED regimen, at dosage of
20–60 mg per die, in three daily doses, according
to clinical response and tolerability. Associated
AEDs were CBZ in eight patients, PB and PHT in
four, LTG in two and VGB in one. Eight patients
were taking two drugs, with an average of 1.72
AED per patient.
Previous therapy remained unchanged during
baseline and add-on phase.
The GTs group was matched with a small
group of patients affected from DRPEs related to
a miscellanea of lesional aetiologies, treated with
open-label TGB add-on, and comparable proto-
col, in the same period of time. This group was
formed by 12 patients (8 M, 4F; age: 23–60 years,
mean: 35); the syndromic diagnosis was temporal
lobe epilepsy in nine, and frontal (FLE), parietal
and occipital lobe epilepsy in the other three
patients. The specific underlying aetiology was:
hyppocampal sclerosis in five, perinatal injury in
three, cortical dysplasia (CD) in two, post-surgical
malacia in one, and Rasmussen encephalitis (pre-
viously treated with subtotal callosotomy, too) in
another one. Epilepsy was of long-duration (3–40
years, mean: 21.5) and severe in all of them, with
at least five seizure per month, and more than 1
per day in three cases; associated treatment was
1–3 AEDs (mean: 1.91 per patient): CBZ in six,
OXC in four, LTG and CLB in three, PB and
VPA in two, PHT, TPM and FLB in one. Pa-
tients are considered reponders if the frequency of
seizures decreased, in a follow-up period at least
of 1 year, more than 50% of baseline, without
intolerable adverse effects (AEs).
3. Results
3.1. GTs group
Seven patients (63.6%) are responders, with
three (27.2%) seizure-free (SF), without difference
by seizure type. Tolerability of TGB was good in
all but two patients; referred AEs were nausea in
one case, not leading to drop-out, and tiredness in
another, not-responder, patient.
Patient 8 shifted her CPS in very frequent SPS,
with disagreeable epigastric aura, so leading to
drop-out. No relevant changes in plasma concen-
tration of concomitant AEDs was noticed during
add-on of TGB.
3.2. Matching group
Two patients (16.6%) are responders, without
SF cases. One patient, with FLE, and another
with CD, dropped-out during titration phase, due
to worsening of seizure frequency and severity;
another patient dropped-out, because of appear-
ance of myoclonus. Furthermore, minor AEs (as-
thenia, dizziness) were reported in two
non-responders patients.
4. Discussion
Value of this clinical observation is limited and
it should be interpreted with criticism. The sample
of patients is small, and possible confusion can be
related to the natural evolution of disease. In
addition, this open-label add-on treatment can
S. Striano et al. / Epilepsy Research 49 (2002) 81–85 83
T
ab
le
1
C
lin
ic
al
da
ta
of
G
T
s
gr
ou
p
K
in
d
of
tu
m
or
Se
x,
R
ad
io
-t
he
ra
py
Se
iz
ur
e
ty
pe
F
re
qu
en
cy
A
dd
-o
n
A
E
D
s
P
at
ie
nt
T
G
B
m
ax
do
se
Su
rg
ic
al
O
ut
co
m
e
an
d
lo
ca
liz
at
io
n
ye
ar
s
(m
g
pe
r
di
e)
re
se
ct
io
n
(y
ea
r)
Y
es
1
C
P
S,
SP
S
L
ef
t
te
m
po
ra
l

10
pe
r
[G
V
G
,P
B
]
60
R
es
po
nd
er
a
M
,2
0
P
ar
ti
al
(1
99
5)
as
tr
oc
yt
om
a
(l
ow
m
on
th
C
B
Z
gr
ad
e)
2
P
ar
ti
al
(1
99
1)
Y
es
C
P
S

1
pe
r
da
y
[P
H
T
]
L
ef
t
fr
on
ta
l
45
R
es
po
nd
er
M
,3
3
C
B
Z
+
L
T
G
ol
ig
od
en
dr
og
lio
m
a
(r
el
ap
se
)
Y
es
SP
S

2
pe
r
m
on
th
P
B
+
P
H
T
R
ig
ht
fr
on
ta
l
30
3
R
es
po
nd
er
M
,3
6
P
ar
ti
al
(1
99
8)
ol
ig
od
en
dr
og
lio
m
a
(l
ow
gr
ad
e)
R
ig
ht
fr
on
ta
l
P
ar
ti
al
(1
99
9)
Y
es
SP
S,
G
T
C
S

10
pe
r
P
B
+
P
H
T
30
N
ot
re
sp
on
de
r
M
,4
9
4
m
on
th
m
ul
ti
fo
rm
gl
io
bl
as
to
m
a
SP
S
5

1
pe
r
da
y
R
ig
ht
pa
ri
et
al
C
B
Z
30
R
es
po
nd
er
M
,2
9
P
ar
ti
al
(1
99
7)
Y
es
ol
ig
od
en
dr
og
lio
m
a
Y
es
C
P
S

1
pe
r
da
y
C
B
Z
+
P
B
45
P
ar
ti
al
(1
98
9)
SF
6
F
,2
0
L
ef
t
te
m
po
ra
l
pi
lo
ci
ty
c
as
tr
oc
yt
om
a
C
P
S

1
pe
r
da
y
[P
B
]
M
,3
3
30
7
N
ot
re
sp
on
de
ra
L
ef
t
oc
ci
pi
ta
l
T
ot
al
(1
98
1)
N
o
C
B
Z
+
G
V
G
ol
ig
od
en
dr
og
lio
m
a
C
P
S

10
pe
r
N
o
C
B
Z
+
L
T
G
P
ar
ti
al
(1
99
6)
30
8
N
ot
re
sp
on
de
rb
L
ef
t
te
m
po
ra
l
F
,4
5
m
on
th
ol
ig
od
en
dr
og
lio
m
a
SP
S
9

1
pe
r
da
y
R
ig
ht
ro
la
nd
ic
[C
N
P
]
M
,5
2
30
SF
N
o
N
o
as
tr
oc
yt
om
a
P
H
T
+
P
B
C
P
S

2
pe
r
m
on
th
[P
B
,G
P
T
]
C
B
Z
30
T
ot
al
(1
98
9)
SF
R
ig
ht
te
m
po
ra
l
F
,3
1
N
o
10
ol
ig
od
en
dr
og
lio
m
a
Y
es
11
C
P
S
L
ef
t
fr
on
ta
l

15
pe
r
F
,1
0
P
B
+
C
B
Z
20
N
ot
re
sp
on
de
r
P
ar
ti
al
(1
99
9)
m
on
th
as
tr
oc
yt
om
a
(r
el
ap
se
)
[],
pr
ev
io
us
,
di
sc
on
ti
nu
ed
A
E
D
s;
SP
S,
si
m
pl
e
pa
rt
ia
l
se
iz
ur
e;
C
P
S,
co
m
pl
ex
pa
rt
ia
l
se
iz
ur
es
;
G
T
C
S,
se
co
nd
ar
ily
ge
ne
ra
liz
ed
to
ni
c
cl
on
ic
se
iz
ur
es
;
SF
,
se
iz
ur
e-
fr
ee
.
a
A
dv
er
se
ef
fe
ct
s.
b
A
pp
ea
ra
nc
e
of
SP
S.
S. Striano et al. / Epilepsy Research 49 (2002) 81–8584
not be reasonably compared with double blind,
randomized, placebo-controlled, fixed drug regu-
latory trials.
In the attempt to evidence a possible aetiology-
specific efficacy, we matched the GTs group with
a group of very severe epilepsy related to a variety
of lesional aetiologies. However, also this com-
parison must be interpreted cautiously. Age of
patients, type and frequency of seizures, number
and type of associated AEDs are similar in both
groups, but duration of epilepsy is much longer in
the control than in GTs group (21.5 vs. 7.36
years). Therefore, the long duration of epilepsy
could justify the very low rate of responders in the
matching group.
However, despite these limitations, TGB seems
to be very effective in DRPE related to cerebral
GTs: about 2/3 of our patients are responders,
with higher rate of efficacy compared with Litera-
ture data (Loiseau, 1999; Crawford et al., 2001);
in addition, tolerability is generally good.
However, the hypothesis of a relatively specific,
aetiology-related, efficacy of TGB in DRPE due
to GTs should be confirmed in larger, policentric,
double blind trials.
Possible role of TGB in GTs could be related to
interaction of underlying pathology with its spe-
cific mechanism of action. TBG acts through the
inhibition of GABA reuptake, thus increasing its
concentration in brain (Fink-Jensen et al., 1992;
During et al., 1992). GABA reuptake is realized
by at least four different transporters (Borden,
1996; Roettger and Amara, 1999); TGB blocks
mostly GAT-1, and, in a lesser extent, GAT-3
(Borden et al., 1994). In the rat, GAT-1 is pre-
dominantly localized to GABAergic neural termi-
nals, but, at least in some cerebral regions, it is
found additionally or exclusively in glia (Minelli
et al., 1995); therefore, higher efficacy in GTs
could simply be related to particular plenty of
GAT-1 in neoplastic tissue derived from cells of
glial line. However, the specific mechanism lead-
ing to epileptic seizures in patients with GTs is
still debated. In particular, is not clear whether
the tumor transforms the normal surrounding
brain tissue into an epileptic structure, thus induc-
ing the seizures, or if neoplastic tissue itself con-
tains epileptogenic cells. Recent in vitro studies
showed that brain slices obtained from human
surgical material from oligodendroglioma can
generate action potentials, so making as electri-
cally excitable cells, at least in first days of its
growth.
In other words, cells derived from glial line
could transitorily acquire neuronal properties,
and serving as epileptogenic substrate (Ketten-
mann, 1999). Obviously, data from a clinical trial
are not enough to give sufficient answers in favor
of an ipothesis or the other one; in vitro studies
on neoplastic tissue, e.g. with patch-clamp tech-
nique, could probably offer more precise informa-
tions about TGB mechanism of action in these
cell population.
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